- Author:
Minji KIM
1
;
Jihyun KIM
Author Information
- Publication Type:Review
- Keywords: Atopic dermatitis; Biomarker; Endotype; Phenotype; Precision medicine
- MeSH: Biological Products; Biomarkers; Continental Population Groups; Dermatitis, Atopic; Humans; Immunoglobulin E; Microbiota; Phenotype; Precision Medicine; Skin; Skin Diseases
- From:Allergy, Asthma & Respiratory Disease 2020;8(1):9-14
- CountryRepublic of Korea
- Language:Korean
- Abstract: Atopic dermatitis (AD) is the most common chronic inflammatory skin disease, characterized by a complex pathophysiology and a variety of clinical phenotypes. However, heterogeneous clinical phenotypes are generally not considered in treating AD. To date, phenotypes and endotypes have been proposed to classify AD mainly based on differences in age, IgE, severity, race, skin barrier dysfunction, immune (Th2/Th17/Th22) polarization, and skin microbiome. Various biologics to target polarized immune pathways, including dupilumab, have been newly developed for the personalized treatment of moderate-to-severe AD. Further understanding of AD pathophysiology and identification of novel biomarkers will not only allow clinically useful stratification of AD and but also achieve precision medicine for the prevention and treatment of AD.

